OpenPV Signal Explorer
FAERS disproportionality dashboard
← All drugs
Drug

Clindamycin Phosphate Topical

206 flagged reaction(s) · 3,289 total co-reports · max PRR 15.0
Important: Reactions below are the flagged terms from this drug’s FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate disproportionality in spontaneous reporting, not causation. Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
Reaction Co-reports (a) PRR ROR Signal
1 Toxic Skin Eruption 25 15.0 15.1 signal
2 Toxic Epidermal Necrolysis 31 12.5 12.6 signal
3 Sleep Apnoea Syndrome 34 10.8 10.9 signal
4 Drug Eruption 31 10.7 10.8 signal
5 Clostridium Difficile Infection 37 10.4 10.5 signal
6 Scar 27 9.6 9.6 signal
7 Drug Reaction With Eosinophilia And Systemic Symptoms 39 9.3 9.4 signal
8 Rash Maculo-papular 33 9.0 9.1 signal
9 Folliculitis 15 8.8 8.8 signal
10 Clostridium Difficile Colitis 14 8.0 8.0 signal
11 Eosinophilia 22 7.6 7.7 signal
12 Drug Hypersensitivity 228 7.1 7.6 signal
13 Skin Reaction 16 6.9 6.9 signal
14 Skin Lesion 30 6.7 6.7 signal
15 Application Site Pain 24 6.6 6.7 signal
16 Product Packaging Issue 10 6.5 6.6 signal
17 Cyst 13 6.3 6.4 signal
18 Pharyngeal Swelling 10 6.3 6.4 signal
19 Drug Ineffective For Unapproved Indication 57 6.2 6.3 signal
20 Product Odour Abnormal 10 5.8 5.9 signal
21 Flank Pain 9 5.8 5.8 signal
22 Oesophagitis 10 5.5 5.6 signal
23 Tooth Fracture 10 5.5 5.5 signal
24 Acute Respiratory Distress Syndrome 16 5.5 5.5 signal
25 Premature Delivery 14 5.3 5.3 signal
26 Renal Failure Acute 36 5.1 5.1 signal
27 Hepatic Steatosis 15 4.9 4.9 signal
28 Cholestasis 15 4.8 4.8 signal
29 Skin Ulcer 20 4.7 4.7 signal
30 Bursitis 9 4.5 4.5 signal
31 Acute Hepatic Failure 10 4.5 4.5 signal
32 Gingival Bleeding 10 4.4 4.4 signal
33 Stevens-johnson Syndrome 16 4.4 4.4 signal
34 Skin Infection 8 4.3 4.4 signal
35 Fistula 8 4.3 4.3 signal
36 Body Temperature Decreased 7 4.3 4.3 signal
37 Dermatitis Contact 8 4.3 4.3 signal
38 Cholecystectomy 8 4.3 4.3 signal
39 Localised Infection 17 4.3 4.3 signal
40 Abscess 11 4.2 4.2 signal
41 Poor Quality Product Administered 7 4.2 4.2 signal
42 Foot Fracture 13 4.1 4.2 signal
43 Petechiae 7 4.1 4.1 signal
44 Acne 51 4.1 4.1 signal
45 Sinus Congestion 9 4.0 4.0 signal
46 Therapy Partial Responder 10 4.0 4.0 signal
47 Glomerular Filtration Rate Decreased 8 4.0 4.0 signal
48 Retinal Detachment 6 4.0 4.0 signal
49 Product Packaging Quantity Issue 7 3.9 3.9 signal
50 Bipolar Disorder 7 3.9 3.9 signal
51 Disseminated Intravascular Coagulation 9 3.9 3.9 signal
52 Anaphylactic Reaction 35 3.9 3.9 signal
53 Foot Deformity 7 3.8 3.8 signal
54 Impaired Gastric Emptying 8 3.8 3.8 signal
55 Obesity 10 3.8 3.8 signal
56 Cellulitis 31 3.7 3.8 signal
57 Blood Pressure Systolic Increased 12 3.7 3.7 signal
58 Anhedonia 16 3.7 3.7 signal
59 Bone Loss 9 3.6 3.6 signal
60 Blister 33 3.6 3.6 signal
61 Tubulointerstitial Nephritis 11 3.6 3.6 signal
62 Tooth Abscess 6 3.6 3.6 signal
63 Dermatitis 12 3.5 3.5 signal
64 Rash 251 3.5 3.7 signal
65 Rash Papular 13 3.5 3.5 signal
66 Eczema 29 3.5 3.5 signal
67 Skin Disorder 19 3.5 3.5 signal
68 Fungal Infection 19 3.5 3.5 signal
69 Hepatocellular Injury 8 3.4 3.4 signal
70 Application Site Irritation 7 3.4 3.4 signal
71 Bronchospasm 8 3.4 3.4 signal
72 Paralysis 8 3.4 3.4 signal
73 Limb Injury 15 3.4 3.4 signal
74 Rash Macular 19 3.3 3.3 signal
75 Red Blood Cell Sedimentation Rate Increased 6 3.3 3.3 signal
76 Face Oedema 9 3.2 3.2 signal
77 Myocarditis 6 3.2 3.2 signal
78 Scab 6 3.2 3.2 signal
79 Burning Sensation 37 3.2 3.2 signal
80 Laceration 5 3.2 3.2 signal
81 Autoimmune Disorder 5 3.2 3.2 signal
82 Post Procedural Complication 10 3.2 3.2 signal
83 Drug-induced Liver Injury 16 3.1 3.2 signal
84 Throat Tightness 14 3.1 3.2 signal
85 Vasculitis 6 3.1 3.1 signal
86 Post Procedural Haemorrhage 6 3.1 3.1 signal
87 Vitreous Floaters 5 3.1 3.1 signal
88 Rash Erythematous 24 3.1 3.1 signal
89 Lip Swelling 17 3.1 3.1 signal
90 Inflammatory Bowel Disease 5 3.1 3.1 signal
91 Drug Resistance 13 3.1 3.1 signal
92 Sinus Disorder 10 3.1 3.1 signal
93 Taste Disorder 10 3.0 3.0 signal
94 Angioedema 22 3.0 3.0 signal
95 Erythema 101 3.0 3.0 signal
96 Hepatic Cytolysis 6 3.0 3.0 signal
97 Respiratory Depression 6 3.0 3.0 signal
98 Agranulocytosis 9 3.0 3.0 signal
99 Skin Haemorrhage 7 2.9 2.9 signal
100 Coagulopathy 8 2.9 2.9 signal
101 Dermatitis Allergic 6 2.9 2.9 signal
102 Lymphadenopathy 17 2.9 2.9 signal
103 Pallor 13 2.9 2.9 signal
104 Intentional Dose Omission 13 2.9 2.9 signal
105 Wound 13 2.8 2.8 signal
106 Poor Quality Sleep 10 2.8 2.8 signal
107 Ankylosing Spondylitis 6 2.8 2.8 signal
108 Gastrointestinal Pain 5 2.8 2.8 signal
109 Dry Skin 60 2.8 2.8 signal
110 Immune System Disorder 6 2.8 2.8 signal
111 Multi-organ Failure 8 2.8 2.8 signal
112 Tooth Infection 6 2.8 2.8 signal
113 Dental Caries 5 2.7 2.7 no signal
114 Quality Of Life Decreased 6 2.7 2.7 signal
115 Restless Legs Syndrome 8 2.7 2.7 signal
116 Shock 10 2.7 2.7 signal
117 Conjunctivitis 8 2.6 2.6 signal
118 Increased Tendency To Bruise 4 2.6 2.6 no signal
119 Swelling Face 28 2.6 2.6 signal
120 Palmar-plantar Erythrodysaesthesia Syndrome 10 2.6 2.6 signal
121 Eyelid Oedema 5 2.6 2.6 no signal
122 Suicidal Ideation 39 2.6 2.6 signal
123 Dermatitis Atopic 21 2.5 2.6 signal
124 Deafness 11 2.5 2.6 signal
125 Rash Generalised 11 2.5 2.5 signal
126 Application Site Erythema 11 2.5 2.5 signal
127 Pruritus 157 2.5 2.6 signal
128 Faeces Discoloured 9 2.5 2.5 signal
129 Treatment Failure 34 2.5 2.5 signal
130 Surgery 24 2.5 2.5 signal
131 Skin Exfoliation 34 2.5 2.5 signal
132 Melaena 9 2.5 2.5 signal
133 Therapeutic Product Effect Decreased 18 2.5 2.5 signal
134 Tooth Disorder 9 2.4 2.4 signal
135 Gastric Disorder 14 2.4 2.4 signal
136 Haematochezia 22 2.4 2.4 signal
137 Hypotonia 4 2.4 2.4 no signal
138 Vaginal Discharge 4 2.4 2.4 no signal
139 Skin Irritation 18 2.4 2.4 signal
140 Bone Marrow Failure 8 2.4 2.4 signal
141 Gallbladder Disorder 7 2.4 2.4 signal
142 Anaphylactic Shock 10 2.4 2.4 signal
143 Swollen Tongue 12 2.3 2.3 signal
144 Mucosal Inflammation 10 2.3 2.3 signal
145 Nodule 5 2.3 2.3 no signal
146 Lung Infection 6 2.3 2.3 no signal
147 Therapeutic Response Shortened 12 2.3 2.3 signal
148 Premature Baby 11 2.2 2.2 signal
149 Eye Pruritus 12 2.2 2.2 signal
150 Maternal Exposure During Pregnancy 32 2.2 2.2 signal
151 Interstitial Lung Disease 17 2.1 2.1 signal
152 Activities Of Daily Living Impaired 7 2.1 2.1 no signal
153 International Normalised Ratio Increased 10 2.1 2.1 signal
154 Paranoia 6 2.1 2.1 no signal
155 Metastases To Liver 6 2.1 2.1 no signal
156 Myoclonus 4 2.0 2.0 no signal
157 Therapeutic Response Unexpected 15 2.0 2.0 signal
158 Spinal Operation 4 2.0 2.0 no signal
159 Schizophrenia 4 2.0 2.0 no signal
160 Skin Burning Sensation 23 2.0 2.0 no signal
161 Muscle Spasticity 4 2.0 2.0 no signal
162 Erythema Multiforme 3 2.0 2.0 no signal
163 Psoriasis 42 1.9 2.0 no signal
164 Skin Fissures 6 1.9 1.9 no signal
165 Hallucination, Auditory 5 1.9 1.9 no signal
166 Mydriasis 4 1.9 1.9 no signal
167 Product Quality Issue 42 1.9 1.9 no signal
168 Coeliac Disease 3 1.9 1.9 no signal
169 Eye Haemorrhage 4 1.8 1.8 no signal
170 Full Blood Count Decreased 6 1.8 1.8 no signal
171 Blindness Unilateral 4 1.7 1.7 no signal
172 Cardiovascular Disorder 7 1.7 1.7 no signal
173 Product Availability Issue 6 1.6 1.6 no signal
174 Status Epilepticus 3 1.6 1.6 no signal
175 Blood Count Abnormal 4 1.6 1.6 no signal
176 Vaginal Haemorrhage 11 1.6 1.6 no signal
177 Madarosis 3 1.6 1.6 no signal
178 Expired Product Administered 8 1.5 1.5 no signal
179 Injection Site Extravasation 3 1.5 1.5 no signal
180 Hair Colour Changes 3 1.4 1.4 no signal
181 Metastases To Central Nervous System 3 1.4 1.4 no signal
182 Drug Administration Error 7 1.4 1.4 no signal
183 Psoriatic Arthropathy 9 1.4 1.4 no signal
184 Hair Texture Abnormal 3 1.3 1.3 no signal
185 Pelvic Pain 4 1.3 1.3 no signal
186 Application Site Rash 3 1.3 1.3 no signal
187 Drug Prescribing Error 4 1.2 1.2 no signal
188 Product Physical Issue 4 1.2 1.2 no signal
189 Accidental Exposure To Product 20 1.2 1.2 no signal
190 Pregnancy 4 1.2 1.2 no signal
191 Foetal Exposure During Pregnancy 15 1.1 1.1 no signal
192 Application Site Pruritus 4 1.1 1.1 no signal
193 Abortion Spontaneous 7 1.1 1.1 no signal
194 Injection Site Urticaria 4 1.0 1.0 no signal
195 Drug Effective For Unapproved Indication 4 0.8 0.8 no signal
196 Injection Site Haemorrhage 10 0.8 0.8 no signal
197 Drug Exposure During Pregnancy 4 0.7 0.7 no signal
198 Multiple Sclerosis Relapse 8 0.7 0.7 no signal
199 Device Issue 9 0.6 0.6 no signal
200 Gynaecomastia 3 0.6 0.6 no signal
201 Device Dislocation 4 0.6 0.6 no signal
202 Myelosuppression 3 0.5 0.5 no signal
203 Device Breakage 3 0.5 0.5 no signal
204 Renal Cancer 3 0.4 0.4 no signal
205 Device Difficult To Use 4 0.4 0.4 no signal
206 Drug Dose Omission By Device 3 0.2 0.2 no signal